证券代码：002612 证券简称：朗姿股份 公告编号：2023-073 朗姿股份有限公司 关于为全资子公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、朗姿股份有限公司（以下简称"朗姿股份"或"公司"） 第五届董事会 第三次会议和 2022 年度股东大会分别审议通过了《关于 2023 年度对外担保额度 的议案》，同意 2023 年度公司及其控股子公司的对外担保总额不超过 40.6 亿元 （以下除非特别注明，所称"元"均指"人民币元"），其中对资产负债率未超 过 70%的控股子公司担保额度为 40 亿元，对资产负债率超过 70%的控股子公司 担保额度为 0.6 亿元。截止本公告披露日，公司及控股子公司对外担保总余额为 81,510 万元，占公司 2022 年度经审计净资产的 28.32%；其中，实际被担保方北 京莱茵服装有限公司资产负债率超过 70%，对资产负债率超过 70%的控股子公 司担保余额为 1,000 万元。 2、公司及控股子公司未对合并报表范围外的公司提供担保。 3、公司及控股子公司未发生逾期担保、涉及诉讼的担保及因 ...

证券代码:002612 证券简称:朗姿股份 朗姿股份有限公司 投资者关系活动记录表 | --- | --- | |------------------------|-----------------------------| | | 特定对象调研 □分析师会议 | | 投资者关系活 | □媒体采访 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | | | 活动参与人员 | 42 家机构 46 | | 时间 | 2023 年 8 月 30 | | 地点 | 朗姿大厦 | | 形式 | 线上会议 | | 上市公司接待 | 副总经理、董事会秘书:王建优 | | 人员姓名 | 证券事务代表:易文贞 | | | | | | 1 | | | 2023 | | | 上年同期同比上升 | | | 增长 1.72% | | | 扣非后归母净利润 | | | 2 | | 交流内容及具体问答记录 | 2023 年半年度, | | | 元,同比上升 | | | | | | 基本每股收益 | | | 净资产收益率为 | | | 4、总资产和净资产 | | | 截止 2023 年 | | | 末下降 0. ...

Financial Performance - The company's operating revenue for the reporting period reached ¥2,312,932,702.11, representing a year-on-year increase of 21.48% compared to ¥1,903,918,742.71 in the same period last year[13]. - The net cash flow generated from operating activities increased by 209.25% to ¥402,202,565.91, up from ¥130,058,674.16 in the previous year, driven by revenue growth and corresponding increases in collections[13]. - Fashion women's segment reported revenue of ¥908.74 million, a year-on-year increase of 21.72%[15]. - Medical beauty segment achieved revenue of ¥906.21 million, with a year-on-year growth of 25.15%[15]. - Online sales generated revenue of ¥369.02 million, reflecting a significant year-on-year increase of 62.07%[21]. - Direct sales revenue reached ¥903.82 million, with a year-on-year growth of 23.15%[21]. - Investment income for the reporting period was 46.50 million yuan, representing 28.33% of total profit[52]. - Total assets as of June 30, 2023, amount to 119,184.55 million yuan, with a net profit of 29.80 million yuan for the first half of 2023[35]. Business Strategy and Development - The company has adjusted its main brand in the domestic infant and child market from "Akabong" to the high-end children's clothing brand "ETTOI" to better meet consumer demand[2]. - The company has established a total of 547 offline sales terminals and 44 online channels for its women's clothing business, with a loyal and stable customer base[11]. - The company has invested in the Korean brand Akabong, which has over 10 series brands in the infant and child products market, and is focusing on the high-end children's clothing brand Ettoi in China[9]. - The company has expanded its medical beauty business, with brands like "Milan Baiyu" and "Jingfu Medical Beauty" operating multiple chain institutions across various cities[12]. - The company has implemented a digital transformation strategy in its women's clothing business, enhancing supply chain management and customer relationship management capabilities[5]. - The company plans to further develop its new retail channels, with significant growth in Tmall and Douyin platforms, indicating a strong focus on digital sales strategies[5]. - The company plans to expand its market presence in first and second-tier cities, focusing on urban elite women[30]. - The company is focusing on developing new retail models leveraging big data and AI to meet personalized consumer demands[72]. - The company aims to strengthen its competitive position in the mid-to-high-end women's clothing market through design innovation and brand diversification[72]. - The company has expanded its business model from solely fashion women's wear to include medical beauty and green infant and child sectors, aiming for a synergistic operational strategy[73]. Operational Efficiency - The company has established a comprehensive marketing network and supply chain system, integrating self-operated and distribution models, as well as online and offline sales channels[11]. - The company has launched new sales channels including Douyin and WeChat mini-programs in 2023[26]. - The company plans to enhance its online business and supply chain management to improve operational efficiency and marketing precision[69]. - The company is addressing risks related to rising labor costs and market competition by enhancing management capabilities and resource sharing among its medical beauty brands[72]. - The company is enhancing its operational capabilities in the medical beauty sector through increased investment and strategic partnerships to maintain competitive advantages[93]. Environmental Responsibility - The company has established a water management system to reduce waste, including the installation of water-saving devices and regular inspections[108]. - The company’s products have passed over 300 harmful substance tests and received the OEKO-TEX® MADE IN GREEN label, demonstrating commitment to sustainability[109]. - The company has committed to avoiding related party transactions and ensuring fair pricing in any necessary transactions post-acquisition[114]. - The company has committed to providing at least RMB 500 million to support its medical beauty business strategy after the completion of a share reduction plan by a major shareholder[116]. - The company has implemented measures to reduce carbon emissions, including using natural plant dyes for silk products[130]. - The company’s wastewater management includes centralized collection and treatment to meet discharge standards, with regular third-party inspections[108]. - The company has a strong focus on environmental responsibility, ensuring compliance with national standards for wastewater discharge[109]. - The company’s employee awareness programs emphasize energy conservation and responsible resource usage across all facilities[108]. Shareholder and Governance - The company maintained a stable shareholding structure, with key executives holding a total of 2,600,000 shares, representing 0.57% of the total share capital[85]. - The company has initiated a third employee stock ownership plan, with total employee self-raised funds amounting to CNY 18,960,000[83]. - The company held several shareholder meetings with participation rates of 54.93% and 55.07% in January and July 2023, respectively, indicating strong investor engagement[99]. - The company implemented the third employee stock ownership plan, which was approved by the board and shareholders in early 2021[101]. - The company has committed to maintaining independence in operations, assets, personnel, finance, and organization post-acquisition[138]. - The company has pledged to minimize related party transactions and ensure that any necessary transactions are conducted at market rates with independent third parties[138]. - The company reported a beginning balance of 34,845,000 CNY in related party transactions, with new additions of 435,159,300 CNY and repayments of 249,500,000 CNY during the reporting period[144]. - The interest rate on related party borrowings was set at 4.00%, with interest accrued during the period amounting to 515,930 CNY[144]. - The company confirmed that there were no significant litigation or arbitration matters during the reporting period[140]. - The company has not engaged in any leasing, contracting, or custodial arrangements during the reporting period[149]. Risks and Challenges - The company faces risks from rising human resource costs, which it plans to mitigate through refined management practices and increased automation[88][89]. - The company is addressing risks related to medical accidents and personnel turnover by implementing strict standards and a robust internal training and recruitment strategy[91][92]. - The company has identified risks in the mid-to-high-end women's clothing market due to rapidly changing consumer demands and fashion trends, which could impact brand recognition and performance[93]. - The company has not experienced any bankruptcy reorganization matters during the reporting period[119]. - The company has not faced any administrative penalties related to environmental protection during the reporting period[133].

一、董事会会议召开情况 证券代码：002612 证券简称：朗姿股份 公告编号：2023-069 朗姿股份有限公司 第五届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 朗姿股份有限公司（以下简称"公司"或"朗姿股份"）第五届董事会第十一次 会议通知于 2023 年 8 月 24 日以传真、邮件等通知方式发出，经 5 位董事一致同 意，于 2023 年 8 月 29 日以通讯及现场会议方式召开。会议由董事长申东日先生 主持，会议应出席董事 5 人，实际出席 5 人。公司监事及高级管理人员列席了本 次会议。本次会议的召开符合《中华人民共和国公司法》《朗姿股份有限公司章 程》《朗姿股份有限公司董事会议事规则》的有关规定，合法有效。 二、董事会会议审议情况 1、审议并通过了公司《2023 年半年度报告》及《2023 年半年度报告摘要》 董事会认为：公司《2023 年半年度报告》及《2023 年半年度报告摘要》符 合法律、行政法规、中国证监会和深圳证券交易所的相关规定，报告内容真实、 准确、完整，不存在任何虚假记载、误导性陈述或者重大遗漏。 ...

证券代码：002612 证券简称：朗姿股份 公告编号：2023-070 朗姿股份有限公司 第五届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 朗姿股份有限公司（以下简称"公司"或"朗姿股份"）第五届监事会第七次会 议通知于 2023 年 8 月 24 日以传真、电子邮件等方式发出，并于 2023 年 8 月 29 日以通讯及现场会议方式召开。会议由监事会主席李婷女士主持，会议应出席监 事 3 名，实际出席监事 3 名，公司董事会秘书王建优先生列席本次会议。会议的 召集和召开符合《中华人民共和国公司法》《朗姿股份有限公司章程》和《朗姿 股份有限公司监事会议事规则》等有关规定，会议合法有效。 二、监事会会议审议情况 1、审议并通过了公司《2023 年半年度报告》及《2023 年半年度报告摘要》 监事会认为：公司《2023 年半年度报告》及《2023 年半年度报告摘要》符 合法律、行政法规、中国证监会和深圳证券交易所的相关规定，报告内容真实、 准确、完整，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：同意 ...

| 非经营性资金 | | 占用方与上 | 上市公司核 | 2023 年期初占 | 2023 年上半年 占用累计发生 | 2023 年上半 | 2023 年上半 | 2023 年上半年 | 占用形成原 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 占用 | 资金占用方名称 | 市公司的关 | 算的会计科 | 用资金余额 | 金额（不含利 | 年占用资金 | 年偿还累计发 | 末占用资金余 | 因 | | | | | 联关系 | 目 | | 息） | 的利息(如有) | 生金额 | 额 | | | | 控股股东、实 际控制人及其 | | | | | | | | | | 非经营性占 | | 附属企业 | | | | | | | | | | 用 | | 小计 | - | - | - | | | | | | - | - | | 前控股股东、 实际控制人及 | | | | | | | | | | 非经营性占 | | 其附属企业 | | | | | | | | | | 用 | | 小计 | - | - | - | ...

朗姿股份有限公司独立董事 关于控股股东及其他关联方占用公司资金、公司对外担保情况 的专项说明和独立意见 根据《上市公司监管指引第8号——上市公司资金往来、对外担保的监管要 求》《深圳证券交易所股票上市规则》《上市公司自律监管指引第1号——主板 上市公司规范运作》等相关规定，作为公司的独立董事，我们对公司2023年半年 度控股股东及其他关联方占用公司资金、公司对外担保情况进行了认真核查，出 具专项报告并发表独立意见： 一、关于公司2023年半年度控股股东及其他关联方占用资金情况的独立意 见 报告期内公司不存在控股股东及其关联方占用上市公司资金的情况。 二、关于公司2023年半年度对外担保情况的独立意见 报告期内，公司所进行的担保均为全资子公司提供的担保或全资子公司为公 司提供的担保，公司及子公司未发生对外担保情况。公司为子公司提供担保，主 要是为支持子公司的经营和长期发展需要，符合全体股东的利益，公司对子公司 的担保风险可控。 公司董事会、股东大会已履行了必要的审批程序，表决程序合法、有效；不 存在损害中小股东利益的情形。 独立董事：朱友干、陈丽京 2023 年 8 月 29 日 ...

证券代码：002612 证券简称：朗姿股份 公告编号：2023-068 朗姿股份有限公司 关于为全资子公司提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、朗姿股份有限公司（以下简称"朗姿股份"或"公司"） 第五届董事会 第三次会议和 2022 年度股东大会分别审议通过了《关于 2023 年度对外担保额度 的议案》，同意 2023 年度公司及其控股子公司的对外担保总额不超过 40.6 亿元 （以下除非特别注明，所称"元"均指"人民币元"），其中对资产负债率未超 过 70%的控股子公司担保额度为 40 亿元，对资产负债率超过 70%的控股子公司 担保额度为 0.6 亿元。截止本公告披露日，公司及控股子公司对外担保总余额为 80,510 万元，占公司 2022 年度经审计净资产的 27.97%；其中，实际被担保方北 京莱茵服装有限公司资产负债率超过 70%，对资产负债率超过 70%的控股子公 司担保余额为 1,000 万元。 2、公司及控股子公司未对合并报表范围外的公司提供担保。 3、公司及控股子公司未发生逾期担保、涉及诉讼的担保及因 ...

关于投资设立医美创业投资基金博恒二号备案完成 暨进展公告 本公司及董事会全体人员保证公告信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 一、设立基金的基本情况 经朗姿股份有限公司（以下简称"公司"）分别于2023年6月16日召开的第五 届董事会第七次会议和2023年7月7日召开的2023年第二次临时股东大会审议通 过，同意公司与参股公司北京朗姿韩亚资产管理有限公司（以下简称"韩亚资管"） 及公司控股股东、实际控制人申东日先生签订附生效条件的《芜湖博恒二号创业 投资合伙企业（有限合伙）合伙协议》（以下简称《有限合伙协议》或"本协议"）。 公司以自有资金3,800万元人民币，作为有限合伙人出资设立医美创业投资基金 —芜湖博恒二号创业投资合伙企业（有限合伙）（以下简称 "博恒二号"）， 朗姿韩亚资管为博恒二号的普通合伙人也即基金管理人。本次投资事项的具体信 息详见公司在巨潮资讯网（www.cninfo.com.cn）、《证券时报》和《上海证券报》 发布的《朗姿股份有限公司关于投资设立医美创业投资基金博恒二号暨关联交易 的公告》（编号：2023-046）。 二、基金备案完成情况 证券代码：0 ...

Financial Performance - The company's operating revenue for Q1 2023 reached ¥1,139,399,566.72, representing a 21.31% increase compared to ¥939,226,348.80 in the same period last year[13] - Net profit attributable to shareholders was ¥62,049,136.05, a significant increase of 6985.13% from a loss of ¥901,205.40 in the previous year[13] - The net cash flow from operating activities was ¥221,827,689.62, up 166.78% from ¥83,149,801.78 in the same period last year[13] - Basic and diluted earnings per share were both ¥0.1402, a substantial increase of 2849.02% from -¥0.0051 in the previous year[13] - The company achieved a 30.68% increase in revenue from its medical beauty business, totaling ¥45,904.01 million[13] - Operating profit for the current period was ¥67,084,783.35, a substantial increase of 667.03% from a loss of ¥11,830,946.94 in the previous year[32] - Total revenue for the first quarter reached ¥1,139,399,566.72, an increase of 21.3% compared to ¥939,226,348.80 in the same period last year[44] - The company's net profit attributable to shareholders was not explicitly stated, but the retained earnings increased to ¥819,529,704.42 from ¥757,480,568.37, indicating a growth of 8.2%[43] - The net profit for the period was $57.26 million, compared to a net loss of $8.39 million in the same period last year[49] - Earnings per share (EPS) for the current period was $0.1402, a recovery from a loss of $0.0051 per share in the previous year[49] Cash Flow and Investments - The net cash flow from financing activities was -$63.77 million, compared to -$223.94 million in the previous period, indicating an improvement[48] - The net increase in cash and cash equivalents was $51.67 million, contrasting with a decrease of $90.89 million in the prior period[48] - Operating cash flow generated was $221.83 million, a significant increase from $83.15 million year-over-year[51] - The total cash inflow from operating activities was $1.18 billion, compared to $1.06 billion in the previous year, showing a growth of about 10.8%[51] - Cash outflows from investing activities totaled $120.51 million, a decrease from $358.62 million in the prior year, indicating reduced investment expenditures[51] - The company reported a net investment income of ¥30,845,384.18, significantly higher than ¥10,955,085.73 from the previous year, marking an increase of 181.5%[44] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,052,712,529.26, reflecting a slight decrease of 0.81% from ¥7,110,249,238.41 at the end of the previous year[23] - The total liabilities increased to ¥3,417,115,780.85 from ¥3,492,390,072.87, a decrease of 2.1%[43] - Long-term borrowings increased to ¥70,000,000.00, marking a 100% increase due to new long-term loans taken during the period[17] - The company's trading financial assets increased by 273.94% to ¥20,652,672.95, up from ¥5,523,031.04 at the end of the previous year[17] - The total assets of the company were ¥7,052,712,529.26, down from ¥7,110,249,238.41, indicating a decrease of 0.8%[43] Shareholder Information - The company reported a total of 69,396 common shareholders at the end of the reporting period, with the largest shareholder holding 47.82% of the shares[24] - Shareholders' equity attributable to the parent company was ¥2,927,047,166.38, a 1.69% decrease from ¥2,878,340,308.08 at the end of the previous year[23] Expenses and Costs - Total operating costs amounted to ¥1,078,495,518.34, up from ¥933,074,035.42, reflecting a rise of 15.6% year-over-year[44] - Research and development expenses for the quarter were ¥23,045,991.84, down from ¥29,054,299.01, a decrease of 20.7%[44] - The company reported a 31.00% increase in payable employee compensation, totaling ¥43,348,585.08, due to increased performance incentives related to the growth in medical beauty business revenue[17]